Aadi Bioscience, Inc. (NASDAQ:AADI – Get Free Report) Chairman Neil Desai sold 40,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $1.71, for a total transaction of $68,400.00. Following the completion of the transaction, the chairman now owns 1,171,543 shares of the company’s stock, valued at approximately $2,003,338.53. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
Neil Desai also recently made the following trade(s):
- On Monday, August 5th, Neil Desai sold 5,652 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.34, for a total transaction of $7,573.68.
- On Thursday, August 1st, Neil Desai sold 15,415 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.50, for a total transaction of $23,122.50.
- On Monday, July 1st, Neil Desai sold 31,348 shares of Aadi Bioscience stock. The shares were sold at an average price of $1.45, for a total transaction of $45,454.60.
Aadi Bioscience Stock Performance
NASDAQ AADI opened at $1.83 on Friday. Aadi Bioscience, Inc. has a one year low of $1.21 and a one year high of $6.29. The company’s 50 day moving average price is $1.53 and its 200 day moving average price is $1.79. The firm has a market capitalization of $44.93 million, a price-to-earnings ratio of -0.72 and a beta of 0.69.
Institutional Trading of Aadi Bioscience
A number of hedge funds have recently made changes to their positions in AADI. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Aadi Bioscience during the second quarter valued at approximately $37,000. Marquette Asset Management LLC acquired a new stake in shares of Aadi Bioscience during the first quarter worth approximately $135,000. Acuitas Investments LLC grew its position in shares of Aadi Bioscience by 10.8% during the second quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock worth $515,000 after buying an additional 34,344 shares in the last quarter. Finally, Decheng Capital LLC acquired a new stake in shares of Aadi Bioscience during the fourth quarter worth approximately $1,063,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have issued reports on the stock. HC Wainwright reaffirmed a “neutral” rating on shares of Aadi Bioscience in a research note on Wednesday, August 21st. Piper Sandler Companies cut shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 target price on the stock. in a research report on Tuesday, August 27th. Piper Sandler cut shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and decreased their target price for the stock from $5.00 to $1.75 in a research report on Tuesday, August 27th. TD Cowen cut shares of Aadi Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, August 21st. Finally, Jefferies Financial Group cut shares of Aadi Bioscience from a “buy” rating to a “hold” rating and decreased their target price for the stock from $11.00 to $1.50 in a research report on Wednesday, August 21st. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $10.25.
Get Our Latest Stock Analysis on Aadi Bioscience
About Aadi Bioscience
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
Read More
- Five stocks we like better than Aadi Bioscience
- Financial Services Stocks Investing
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
- What is Put Option Volume?
- Top 5 ETFs for Every Investor: From Semiconductors to Defense
- Stock Market Upgrades: What Are They?
- Blade Air Mobility: This Under-the-Radar Stock Could Double Soon
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.